Dry Eye

RTP-008 features sustained immunosuppressant delivery for long-term therapeutic effects.

A Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2025, was assigned by the FDA.

The tool is designed to help with the application of mono-dose, dry eye eyedrop vials more easily and accurately.

MHRA issues precautionary recall for Zaditen eye drops due to potential microbial contamination risk

In addition to Prevent Blindness' usual free resources, the organization is providing a dedicated web page, fact sheets, and graphics in English and Spanish.

ST-100 shows promise as a fast-acting treatment for dry eye disease, offering rapid relief and unique collagen repair mechanisms.

The report divides the research into 7 categories: sex, gender, and hormones; epidemiology; pathophysiology; tear film; pain and sensation; iatrogenic; and clinical trial design.

Aldeyra had received 2 complete response letters (CRL) from the FDA in April 2025 and November 2023 for past submissions.

On the heels of the drug's FDA approval, clinicians weigh in on acoltremon’s (Tryptyr) novel mechanism of action and its potential to address unmet needs in dry eye care

Researchers share that perfluorohexyloctane eye drops offer rapid relief for dry eye disease, enhancing patient comfort before cataract surgery.

The preservative-free, contact lens–friendly drops have been formulated to provide hydration and comfort for dry eyes in a multidose bottle.

Alcon’s dry eye candidate acoltremon 0.003% is a first-in-class thermoreceptor agonist, which stimulates corneal sensory nerves to increase natural tear production to treat the signs and symptoms of dry eye disease.

According to the company, results showed “a meaningful clinical improvement in ocular surface health” and significance for both staining end points at day 15.

Responder analysis was conducted to evaluate the percentage of patients achieving complete symptom resolution across 13 prespecified symptom end points.

CsA Ophthalmic Gel is an innovative cyclosporine gel being developed by Zhaoke in China for the treatment of moderate to severe DED.

Under the Vevye Access for All program, patients with a Klarity-C prescription can switch to Vevye for $59 per bottle.

Nordic Pharma plans to announce commercialization details in the near future for the dry eye disease treatment

Recent estimates show that there are over 2 billion users on Instagram, of which over 726.8 million interact with reels on the platform.

The company stated that the FDA noted at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye should be conducted.

Lab TRIACTIV is powered by “advanced cationic liposomal technology” for dry eye relief.

Patients reported that Miebo significantly reduced overall symptoms severity at the primary endpoint of change from baseline in the severity of overall dry eye symptoms at day 7.

This program is in place for prescriptions of cyclosporine ophthalmic solution 0.1% (VEVYE, Harrow) and promises a $59 price tag per bottle, effective immediately.

Italian investigators reported that ocular surface conditions such as dry eye disease are key factors in perioperative outcomes, even when patients achieve 20/20 vision.

The new formula will help relieve temporary symptoms caused by dryness of the eye.

According to the company, the suffix “-mod” in urcosimod denotes its classification as a modulator of key inflammatory and neuropathic pathways.

Researchers conducted a study to characterize ophthalmic adverse events associated with cosmetics and personal care products that have been reported in the FDA CAERS database.